James M. Kilts
James M. Kilts's purchase track record
How the stock did after each of James M. Kilts's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/23/2026 | SMPL | $991K | -17.2% | pending | — |
| 3/20/2026 | ADV | $50K | +86.4% | +69.0% | +17.6% |
| 3/9/2026 | ADV | $105K | +135.9% | +95.4% | +12.9% |
| 6/2/2025 | ADV | $88K | +50.4% | -19.2% | +14.8% |
| 5/23/2025 | ADV | $99K | +68.8% | -11.0% | +13.8% |
| 5/15/2025 | ADV | $184K | +67.0% | +10.1% | +13.9% |
| 3/14/2025 | ADV | $161K | -15.3% | +11.8% | +16.8% |
| 11/9/2023 | ADV | $370K | +99.5% | +91.8% | +19.9% |
| 9/6/2023 | ADV | $93K | +11.1% | +29.6% | +14.3% |
| 8/23/2023 | ADV | $89K | -4.1% | +42.2% | +12.3% |
| 8/15/2023 | ADV | $14K | -13.4% | +35.9% | +11.6% |
| 5/26/2023 | ADV | $78K | +39.8% | +40.8% | +8.4% |
| 5/18/2023 | ADV | $294K | +45.1% | +34.2% | +7.4% |
| 3/4/2022 | ADV | $659K | -22.6% | -40.0% | -9.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
SMPL featured in skeptical Russell 2000 stock list. The Simply Good Foods Company was included in a recent article highlighting three Russell 2000 stocks that analysts are skeptical of. This mention suggests some caution regarding the stock's current outlook among certain market observers. The company's shares have a wide 52-week range, indicating significant volatility over the past year.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
UFI Secures 3-Year Kaia Deal with BTQ Technologies. BTQ Technologies has entered a three‑year agreement with Kaia to secure LINE NEXT's Unifi Wallet. This partnership will allow UFI’s wallet to be integrated into LINE NEXT’s platform, potentially expanding its user base. The deal may provide a new source of revenue for UFI. The announcement comes as the company’s shares trade within its 52‑week range.
Transaction History
| ADV | ▲ Buy | Grant | 4,477 | $0 | 5/27/2026 | View on chart |
| SMPL | ▲ Buy | Open Market | 80,000 | $991K | 4/23/2026 | View on chart |
| ADV | ▲ Buy | Open Market | 30,999 | $25K | 3/23/2026 | View on chart |
| ADV | ▲ Buy | Open Market | 33,554 | $26K | 3/20/2026 | View on chart |
| ADV | ▲ Buy | Open Market | 16,759 | $12K | 3/11/2026 | View on chart |
| ADV | ▲ Buy | Open Market | 75,368 | $52K | 3/10/2026 | View on chart |
| ADV | ▲ Buy | Open Market | 66,499 | $41K | 3/9/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,660 | $0 | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,175 | $0 | 3/6/2026 | View on chart |
| SMPL | ▲ Buy | Grant | 6,500 | $0 | 1/28/2026 | View on chart |
| SMPL | ▲ Buy | Grant | 1,722 | $0 | 9/6/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 9,700 | $12K | 6/6/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 15,755 | $19K | 6/5/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 5,494 | $7K | 6/4/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 23,314 | $29K | 6/3/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 16,491 | $20K | 6/2/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 19,627 | $24K | 5/30/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 11,400 | $15K | 5/29/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 10,003 | $13K | 5/28/2025 | View on chart |
| ADV | ▲ Buy | Grant | 141,129 | $0 | 5/28/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 26,523 | $32K | 5/27/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 14,100 | $16K | 5/23/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 35,835 | $42K | 5/22/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 24,224 | $30K | 5/21/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 21,122 | $27K | 5/20/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 31,740 | $39K | 5/19/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 27,541 | $35K | 5/16/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 10,005 | $11K | 5/15/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 36,181 | $57K | 3/18/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 27,951 | $46K | 3/17/2025 | View on chart |
| ADV | ▲ Buy | Open Market | 34,708 | $59K | 3/14/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 18,204 | $0 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 773 | $0 | 3/4/2025 | View on chart |
| SMPL | ▲ Buy | Grant | 3,827 | $0 | 9/6/2024 | View on chart |
| ADV | ▲ Buy | Grant | 49,715 | $0 | 5/29/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 17,970 | $0 | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 885 | $0 | 3/3/2024 | View on chart |
| SMPL | ▼ Sell | Other | 895,157 | — | 1/8/2024 | View on chart |
| ADV | ▲ Buy | Open Market | 5,468 | $13K | 11/16/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 17,595 | $42K | 11/15/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 29,720 | $71K | 11/14/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 25,754 | $54K | 11/13/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 60,968 | $118K | 11/10/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 35,976 | $72K | 11/9/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 15,700 | $42K | 9/7/2023 | View on chart |
| SMPL | ▲ Buy | Grant | 3,771 | $0 | 9/6/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 19,167 | $51K | 9/6/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 6,795 | $18K | 8/29/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 1,202 | $3K | 8/28/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 11,618 | $31K | 8/25/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 7,061 | $19K | 8/24/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 6,488 | $18K | 8/23/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 4,000 | $11K | 8/21/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 1,100 | $3K | 8/18/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 100 | $265 | 8/15/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 10,119 | $19K | 6/2/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 9,023 | $17K | 6/1/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 22,196 | $42K | 5/26/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 14,251 | $26K | 5/25/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 13,325 | $23K | 5/24/2023 | View on chart |
| ADV | ▲ Buy | Grant | 98,314 | $0 | 5/24/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 15,200 | $29K | 5/23/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 24,803 | $46K | 5/22/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 35,000 | $65K | 5/19/2023 | View on chart |
| ADV | ▲ Buy | Open Market | 56,089 | $105K | 5/18/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 19,608 | $0 | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 705 | $0 | 3/4/2023 | View on chart |
| SMPL | ▲ Buy | Grant | 3,889 | $0 | 9/6/2022 | View on chart |
| ADV | ▲ Buy | Grant | 40,603 | $0 | 5/25/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 166 | $0 | 3/21/2022 | View on chart |
| ADV | ▲ Buy | Open Market | 17,158 | $95K | 3/8/2022 | View on chart |
| ADV | ▲ Buy | Open Market | 56,209 | $314K | 3/7/2022 | View on chart |
| ADV | ▲ Buy | Open Market | 43,791 | $249K | 3/4/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 13,996 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 335 | $0 | 3/2/2022 | View on chart |
| ADV | ▲ Buy | Grant | 11,666 | $0 | 10/28/2021 | View on chart |
| UFI | ▲ Buy | Grant | 4,540 | $0 | 10/27/2021 | View on chart |
| SMPL | ▲ Buy | Grant | 2,812 | $0 | 9/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Advantage Solutions Reports Q2 2026 Earnings
Advantage Solutions held its Q2 2026 earnings conference call, sharing results and guidance. The call was broadcast on Benzinga. The company discussed its financial performance and future plans. The session follows the stock trading near a key support level and a moderate RSI.
Advantage Solutions Reports Q2 2026 Earnings. Advantage Solutions held its Q2 2026 earnings conference call, sharing results and guidance. The call was broadcast on Benzinga. The company discussed its financial performance and future plans. The session follows the stock trading near a key support level and a moderate RSI.